Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Santen Signs Codevelopment Deal with Doshisha Univ. Startup for Sirolimus Eye Drop
November 19, 2021
- Bayer Yakuhin to Shutter Sales Offices for Better Efficiency and Productivity
November 19, 2021
- Daiichi Sankyo Begins PII for COVID-19 mRNA Vaccine, Eyes 2022 Rollout
November 18, 2021
- Otsuka’s Eczema Drug, 2 More Products Skip November Listing
November 18, 2021
- Aducanumab Gets “Negative Trend Vote” in Europe: Biogen/Eisai
November 18, 2021
- Chugai’s FoundationOne Approved to Identify TMB-High Solid Tumors as Keytruda CDx
November 18, 2021
- Opdivo Regains Top-Selling Title, Japan Pharma Market Grows 4.2% in July-September: IQVIA
November 17, 2021
- Astellas, Pantherna Link Arms on mRNA-Based Regenerative Medicine Research
November 16, 2021
- Kyowa Kirin’s Parkinson’s Med Rejected Again in Europe
November 16, 2021
- Kowa Files Livalo/Ezetimibe Fixed-Dose Combo in Japan
November 16, 2021
- Otsuka’s 9-Month Pharma Sales Up 0.8% on Double-Digit Growth of 4 Global Brands
November 16, 2021
- AbbVie Seeks Crohn’s Disease Nod for Skyrizi in Japan
November 15, 2021
- Eylea Filed for ROP in Premature Babies in Japan, EU: Bayer
November 15, 2021
- Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
- Seikagaku to Launch Clinical Research to Verify Cause of Anaphylaxis after Blue Letter
November 15, 2021
- AstraZeneca’s Japan Healthcare Innovation Hub Grows to 131 Members
November 12, 2021
- Rohto Wants to Wrap Up PII of COVID-19 Cell Therapy in 2022: President
November 12, 2021
- Choseido Resumes Operations after 31-Day Biz Suspension
November 12, 2021
- Over 500 Suzuken Group Staffers Take Voluntary Redundancy
November 12, 2021
- Aikomi, Sumitomo Dainippon Eye Therapeutic App Approval for BPSD by 2027
November 12, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…